#1 Clinical Trials Search in Europe
EU – Europe
AT – Austria
HR – Croatia
CZ – Czech Republic
DK – Denmark
EE – Estonia
FI – Finland
FR – France
DE – Germany
IS – Iceland
IT – Italy
LV – Latvia
LT – Lithuania
NL – Netherlands
NO – Norway
PL – Poland
PT – Portugal
RO – Romania
SK – Slovakia
SI – Slovenia
ES – Spain
SE – Sweden
  • Find a Clinical Trial

    Search Trials by Disease

    Non-small cell lung cancer Breast cancer Plasma cell myeloma Neoplasm Neoplasm malignant Acute myeloid leukaemia Colitis ulcerative Obesity Colorectal cancer metastatic Prostate cancer Crohn's disease Colorectal cancer Dementia Alzheimer's type Ovarian cancer Hepatocellular carcinoma Breast cancer metastatic Dermatitis atopic Asthma Non-small cell lung cancer metastatic Malignant melanoma More trials…
  • Rare Diseases Treatments

    Search Trials by Disease

    Guillain-Barre syndrome Liposarcoma Adenocarcinoma pancreas Raynaud's phenomenon Anaemia Infertility female Fragile X syndrome Hereditary motor and sensory neuropathy Polycystic liver disease Follicular lymphoma stage I Vascular malformation Adenocarcinoma gastric Metastatic malignant melanoma Anaplastic large cell lymphoma T- and null-cell types Anti-myelin-associated glycoprotein associated polyneuropathy More trials…

    Learn about Rare Diseases

    X-linked lymphoproliferative syndrome Alagille syndrome – Treatment Rosai-Dorfman syndrome – Trials in Disease Noonan syndrome Glycogen storage disease type II – Trials in Disease Loeys-Dietz syndrome – Treatment Rhabdomyosarcoma – Diagnostics Mantle cell lymphoma refractory – Life with Disease Hyperoxaluria – Life with Disease Brain stem glioma – Treatment More diseases
  • Vaccine Clinical Trials
  • Pediatric Clinical Trials
  • Resources for Patients

    Browse Innovative Treatments

    Ofloxacin Hydrochloride Follitropin Alfa Linperlisib Vinorelbine Bt-001 Eptacog Alfa (Activated) Tigulixostat Prasterone Lisdexamfetamine Dimesylate Betamethasone Dipropionate Cladribine Tamoxifen Enasidenib Mesilate Orlistat Poa Pratensis Efinopegdutide Mitoxantrone Sodium Phosphate Dodecahydrate Brentuximab Vedotin Pentoxifylline More therapies…

    Learn about Your Condition

    Hydrocephalus Pancreatic fistula Burkitt's lymphoma Renal failure Elderly Endocarditis Peripheral artery restenosis Seasonal allergy Triple positive breast cancer Dementia with Lewy bodies Hypervolaemia Infective uveitis Osteochondrodysplasia Combined immunodeficiency Ligament sprain More diseases
  • Healthy Volunteers
  • Patient Guide
  • Our Partners
  • About Us
  • Contact us
  • Region
    🇪🇺 Europe
    🇦🇹 Austria
    🇭🇷 Croatia
    🇨🇿 Czech Republic
    🇩🇰 Denmark
    🇪🇪 Estonia
    🇫🇮 Finland
    🇫🇷 France
    🇩🇪 Germany
    🇮🇸 Iceland
    🇮🇹 Italy
    🇱🇻 Latvia
    🇱🇹 Lithuania
    🇳🇱 Netherlands
    🇳🇴 Norway
    🇵🇱 Poland
    🇵🇹 Portugal
    🇷🇴 Romania
    🇸🇰 Slovakia
    🇸🇮 Slovenia
    🇪🇸 Spain
    🇸🇪 Sweden

Chronic lymphocytic leukaemia

  • Study of Ibrutinib and Obinutuzumab for Patients with Chronic Lymphocytic Leukemia Who Have Not Received Treatment Before

    Recruiting

    2 1 1 1
    Investigated Diseases:
    • B-cell small lymphocytic lymphoma
    • Chronic lymphocytic leukaemia
    Investigated Drugs:
    • Ibrutinib
    Italy

  • Study on Acalabrutinib, Obinutuzumab, and Venetoclax for Untreated High-Risk Chronic Lymphocytic Leukemia Patients

    Recruiting

    3 1 1 1
    Investigated Diseases:
    • Chronic lymphocytic leukaemia
    Investigated Drugs:
    • Acalabrutinib
    • Obinutuzumab
    • Venetoclax
    Austria Germany Portugal

  • Study on Treating Chronic Lymphocytic Leukemia with Venetoclax and Acalabrutinib for Patients Whose Disease Has Returned After Initial Treatment

    Recruiting

    2 1 1
    Investigated Diseases:
    • Chronic lymphocytic leukaemia
    Investigated Drugs:
    • Acalabrutinib
    • Venetoclax
    Belgium Denmark The Netherlands

  • Study on Acalabrutinib and Obinutuzumab vs. Venetoclax and Obinutuzumab for Newly Diagnosed Chronic Lymphocytic Leukemia Patients

    Recruiting

    3 1 1 1
    Investigated Diseases:
    • Chronic lymphocytic leukaemia
    Investigated Drugs:
    • Acalabrutinib
    • Obinutuzumab
    • Venetoclax
    Poland

  • Study Comparing Pirtobrutinib and Ibrutinib for Patients with Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

    Recruiting

    3 1 1 1
    Investigated Diseases:
    • Chronic lymphocytic leukaemia
    Investigated Drugs:
    • Ibrutinib
    • Pirtobrutinib
    Austria Belgium Czechia France Germany Hungary +3

  • Study on Lisaftoclax and Acalabrutinib for Patients with Previously Treated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

    Recruiting

    3 1 1 1
    Investigated Drugs:
    • Lisaftoclax
    • Zanubrutinib
    • Acalabrutinib
    Belgium Bulgaria Czechia France Germany Hungary +5
Previous Page
1 2 3 4 5 6 … 13
Next Page

Investigational Drugs in This Location

See which drug candidates are part of clinical trials near you. Click for detailed trial information.

Medical Conditions Being Studied in This Location

Explore diseases currently included in clinical trials near you. Click to view trials and details for each condition.

European Clinical Trials Information Network

The European Clinical Trials Information Network is transforming access to clinical trial information for patients across Europe. By overcoming language barriers, our platform allows everyone, regardless of their native language, to easily find relevant and comprehensible clinical trial data. This innovative service connects patients to cutting-edge treatments, creating a unified European community where health and progress transcend borders.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic centres, national regulators, and commercial sponsors. We aim to keep all content accurate and up to date.

Explore the full ecosystem of clinical research in Europe.

The information provided on this website is mainly derived from international public clinical trial databases (CTIS.eu). In addition, we are including supplementary sources, such as information provided by academic centers and national regulators, as well as information supplied by commercial sponsors (pharmaceutical companies and contract research organizations). We try to ensure that the information provided is accurate and up to date.

Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).

The website is published by:
CTIN POLAND sp. z o.o.
with its registered office in Warsaw,
ul. rtm. Witolda Pileckiego 67/109,
02-781 Warsaw, Poland,
entered in the Register of Entrepreneurs of the National Court Register under KRS number 0001111334,
REGON: 528919042, NIP (Tax ID): 9512598637
Contact us

© 2026 CTIN Poland

Privacy Policy

Terms and Conditions

Contact

For Sites and Sponsors

Clinical Trial Locations

We use cookies

The website uses cookies to ensure the proper functioning of the site and to analyze internet traffic. Some cookies are essential for using the service and do not require consent. You can accept all cookies or use only the essential ones. Data is processed in accordance with our Privacy Policy. You have the right to withdraw your consent, access, rectify, delete, or limit the processing of your data at any time.
Numer nieprawidłowy!
Numer nieprawidłowy!